Table 1: Percentage Relative Risk Reduction for Major Events Determined by the Pivotal Clinical Trials of Direct-acting Oral Anticoagulants versus Warfarin.

Variable	Dabigatran 150 mg twice daily (%)	Dabigatran 110 mg twice daily (%)	Rivaroxaban 20 mg once daily (%)	Apixaban 5 mg twice daily (%)	Edoxaban 60 mg once daily (%)	Edoxaban 30 mg once daily (%)
Stroke and systemic embolism	35	n.s.	n.s.	21	n.s.	n.s.
Ischaemic stroke	24	n.s.	n.s.	n.s.	n.s.	↑ 41
Haemorrhagic stroke	74	69	41	49	46	67
Intracranial bleeding	59	70	33	58	53	70
Total mortality	n.s.	n.s.	n.s.	11	n.s.	13
Vascular mortality	15	n.s.	n.s.	n.s.	14	15

Data taken from Connolly et al., 2009,[26] Patel et al., 2011,[27] Granger et al., 2011[28] and Giugliano et al., 2013.[29] n.s. = non-significant.